Vaxcyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Vaxcyte and other ETFs, options, and stocks.

About PCVX

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. 

CEO
Grant E. Pickering
CEOGrant E. Pickering
Employees
507
Employees507
Headquarters
San Carlos, California
HeadquartersSan Carlos, California
Founded
2013
Founded2013
Employees
507
Employees507

PCVX Key Statistics

Market cap
9.59B
Market cap9.59B
Price-Earnings ratio
-7.56
Price-Earnings ratio-7.56
Dividend yield
Dividend yield
Average volume
1.01M
Average volume1.01M
High today
$59.39
High today$59.39
Low today
$57.83
Low today$57.83
Open price
$58.72
Open price$58.72
Volume
146.09K
Volume146.09K
52 Week high
$65.00
52 Week high$65.00
52 Week low
$29.51
52 Week low$29.51

Stock Snapshot

The current Vaxcyte(PCVX) stock price is $59.38, with a market capitalization of 9.59B. The stock trades at a price-to-earnings (P/E) ratio of -7.56.

As of 2026-08-11, Vaxcyte(PCVX) stock has fluctuated between $57.83 and $59.39. The current price stands at $59.38, placing the stock +2.7% above today's low and -0.0% off the high.

Vaxcyte(PCVX) shares are trading with a volume of 146.09K, against a daily average of 1.01M.

During the past year, Vaxcyte(PCVX) stock moved between $29.51 at its lowest and $65.00 at its peak.

During the past year, Vaxcyte(PCVX) stock moved between $29.51 at its lowest and $65.00 at its peak.

Analyst ratings

90%

of 10 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own PCVX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.